December 5, 2024
GSK Partners with Muna Therapeutics to Advance Alzheimer’s Treatment Research
GSK, Muna Therapeutics, Alzheimer’s disease, neurodegenerative diseases, drug research, genetic code analysis, neuroscience, collaboration.
FDA Approves Imfinzi for Limited-Stage Small Cell Lung Cancer, Marking First Systemic Immunotherapy for LS-SCLC
Imfinzi (durvalumab), Limited-stage small cell lung cancer (LS-SCLC), FDA approval, Systemic immunotherapy, ADRIATIC Phase III trial, Breakthrough Therapy Designation, Priority Review
FDA Grants Accelerated Approval to Merus’ Bizengri for NRG1+ Lung and Pancreatic Cancers
Bizengri, NRG1+ cancers, FDA accelerated approval, lung cancer, pancreatic cancer, zenocutuzumab-zbco, Merus N.V.
Amgen Expands in North Carolina with $1 Billion Biomanufacturing Facility
Amgen, North Carolina, biomanufacturing, facility expansion, pharmaceutical industry
Novavax Sells Czech Manufacturing Facility to Novo Nordisk for $200 Million
Novavax, Novo Nordisk, Czech manufacturing facility, cost-cutting, vaccine pipeline development
Cleerly Secures $192M for Heart Attack-Predicting AI Technology
Cleerly, AI, Heart Disease, Coronary Artery Scanning, Funding
Novo Nordisk Invests $409M in New Quality Control Lab in Denmark
Novo Nordisk, quality control lab, Denmark, pharmaceutical investment, biotechnology
Nuvig Therapeutics Secures $161M Series B Funding for Autoimmune Therapy Development
Nuvig Therapeutics, autoimmune therapy, series B funding, Sanofi Ventures, autoimmune diseases, Fc gamma R2B, immunomodulatory therapy
Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases
Nuvig Therapeutics, autoimmune diseases, Phase 2 study, funding, NVG-2089, Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), recombinant Fc Ab fragments, synthetic manufacturing.
Genmab Exercises Option for Second Commercial License Agreement with Scancell Holdings
Genmab, Scancell Holdings, monoclonal antibody, GlyMab platform, licensing agreement, cancer treatment, immunotherapies